ESR1 and neoplasm: Further, the results from this study provide strong in vitro and in vivo evidence that roscovitine confers a tumor-suppressive effect on endocrine therapy-resistant breast tumor cells by inhibiting CDK functions and altering expression of ERα and ER-coregulators, and by promoting apoptosis.